Loading...
Predicting response to Bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.
Collinson, F Hutchinson, M Craven, R Cairns, D Zougman, A Wind, T Gahir, N Messenger, M Jackson, S Thompson, D
Collinson, F
Hutchinson, M
Craven, R
Cairns, D
Zougman, A
Wind, T
Gahir, N
Messenger, M
Jackson, S
Thompson, D
Citations
Altmetric:
Abstract
The aim of this study was to identify and validate novel predictive and/or prognostic serum proteomic biomarkers in patients with epithelial ovarian cancer (EOC) treated as part of the phase III international ICON7 clinical trial.
Description
Date
2013-09-15
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 808.03 KB
Keywords
Type
Article
Citation
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. 2013, 19 (18):5227-39 Clin Cancer Res